Manu Vanaerschot
Manu Vanaerschot
Rapid Response Team, Chan Zuckerberg Biohub
Verified email at czbiohub.org
Title
Cited by
Cited by
Year
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance
T Downing, H Imamura, S Decuypere, TG Clark, GH Coombs, JA Cotton, ...
Genome research 21 (12), 2143-2156, 2011
3842011
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance
S Rijal, B Ostyn, S Uranw, K Rai, NR Bhattarai, TPC Dorlo, JH Beijnen, ...
Clinical Infectious Diseases 56 (11), 1530-1538, 2013
2852013
Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics
AN Cowell, ES Istvan, AK Lukens, MG Gomez-Lorenzo, M Vanaerschot, ...
Science 359 (6372), 191-199, 2018
1182018
Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent
H Imamura, T Downing, F Van den Broeck, MJ Sanders, S Rijal, S Sundar, ...
Elife 5, e12613, 2016
1112016
Evaluation of normalization methods to pave the way towards large-scale LC-MS-based metabolomics profiling experiments
BA Ejigu, D Valkenborg, G Baggerman, M Vanaerschot, E Witters, ...
Omics: a journal of integrative biology 17 (9), 473-485, 2013
912013
Modulation of Aneuploidy in Leishmania donovani during Adaptation to Different In Vitro and In Vivo Environments and Its Impact on Gene Expression
F Dumetz, H Imamura, M Sanders, V Seblova, J Myskova, P Pescher, ...
MBio 8 (3), e00599-17, 2017
852017
Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background
S Decuypere, M Vanaerschot, K Brunker, H Imamura, S Müller, B Khanal, ...
PLoS neglected tropical diseases 6 (2), e1514, 2012
782012
Linking in vitro and in vivo survival of clinical Leishmania donovani strains
M Vanaerschot, I Maes, M Ouakad, V Adaui, L Maes, S De Doncker, ...
PLoS One 5 (8), e12211, 2010
692010
Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain
K Rai, B Cuypers, NR Bhattarai, S Uranw, M Berg, B Ostyn, JC Dujardin, ...
MBio 4 (5), e00611-13, 2013
652013
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
M Vanaerschot, F Dumetz, S Roy, A Ponte-Sucre, J Arevalo, JC Dujardin
Expert review of anti-infective therapy 12 (8), 937-946, 2014
612014
Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden
M Vanaerschot, S De Doncker, S Rijal, L Maes, JC Dujardin, S Decuypere
PloS one 6 (8), e23120, 2011
582011
Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India
P Srivastava, VK Prajapati, M Vanaerschot, G Van der Auwera, ...
Infection, Genetics and Evolution 10 (7), 1145-1150, 2010
582010
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials
Y Antonova-Koch, S Meister, M Abraham, MR Luth, S Ottilie, AK Lukens, ...
Science 362 (6419), 2018
562018
Antileishmanial Activity of a Series of N2,N4-Disubstituted Quinazoline-2,4-diamines
KS Van Horn, X Zhu, T Pandharkar, S Yang, B Vesely, M Vanaerschot, ...
Journal of medicinal chemistry 57 (12), 5141-5156, 2014
562014
Treatment of Visceral Leishmaniasis: Model-Based Analyses on the Spread of Antimony-Resistant L. donovani in Bihar, India
A Stauch, HP Duerr, JC Dujardin, M Vanaerschot, S Sundar, M Eichner
PLoS neglected tropical diseases 6 (12), e1973, 2012
532012
Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex
T Downing, O Stark, M Vanaerschot, H Imamura, M Sanders, ...
Infection, Genetics and Evolution 12 (1), 149-159, 2012
512012
Increased metacyclogenesis of antimony-resistant Leishmania donovani clinical lines
M Ouakad, M Vanaerschot, S Rijal, S Sundar, N Speybroeck, L Kestens, ...
Parasitology 138 (11), 1392-1399, 2011
512011
Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure
M Berg, M Vanaerschot, A Jankevics, B Cuypers, I Maes, S Mukherjee, ...
Molecular microbiology 90 (2), 428-442, 2013
492013
Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race
M Vanaerschot, S Huijben, F Van den Broeck, JC Dujardin
FEMS microbiology reviews 38 (1), 41-55, 2014
482014
LC-MS metabolomics from study design to data-analysis–using a versatile pathogen as a test case
M Berg, M Vanaerschot, A Jankevics, B Cuypers, R Breitling, JC Dujardin
Computational and structural biotechnology journal 4 (5), e201301002, 2013
442013
The system can't perform the operation now. Try again later.
Articles 1–20